Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Medical Virology

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jmv.21902PMID 20872711
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanistic Characterization and Molecular Modeling of Hepatitis B Virus Polymerase Resistance to Entecavir

  2010cited by this paper
• Effect of HIV co‐infection on mutation patterns of HBV in patients with lamivudine‐resistant chronic hepatitis B

  2009cited by this paper
• Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

  2009cited by this paper
• Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes

  2009cited by this paper
• Evaluation of dual priming oligonucleotide-based multiplex PCR for detection of HBV YMDD mutants

  2008cited by this paper
• Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B

  2008cited by this paper
• [RtL164V, a mutation possibly associated with lamivudine resistant HBV].

  2008cited by this paper
• Hepatitis B virus Quantification and Detection of YMDD Mutants in a Single Reaction by Real-Time PCR and Annealing Curve Analysis

  2008cited by this paper
• Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.

  2008cited by this paper
• Determination of lamivudine-resistant variants of hepatitis B virus by denaturing gradient gel electrophoresis: a novel approach to monitoring drug resistance.

  2008cited by this paper
• Prevalence of HBV genotypes in Central and Eastern Europe

  2008cited by this paper
• Telbivudine versus lamivudine in patients with chronic hepatitis B.

  2008cited by this paper
• Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.

  2008cited by this paper
• Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection

  2008cited by this paper
• Hepatitis B virus genotypes and lamivudine resistance mutations in Jordan.

  2008cited by this paper
• The treatment of chronic hepatitis B: Focus on adefovir-like antivirals

  2008cited by this paper
• Resistance issues in treating chronic hepatitis B.

  2008cited by this paper
• The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

  2008cited by this paper
• Should Treatment of Hepatitis B Depend on Hepatitis B virus Genotypes? A Hypothesis Generated from an Explorative Analysis of Published Evidence

  2008cited by this paper
• Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine‐resistant hepatitis B genotypes B and C

  2007cited by this paper
• The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro

  2007cited by this paper
• The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation.

  2007cited by this paper
• Telbivudine versus lamivudine in patients with chronic hepatitis B.

  2007cited by this paper
• Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.

  2007cited by this paper
• Comparison of Mass Spectrometric Analysis and TRUGENE™ HBV Genotyping for Monitoring Lamivudine Resistance in Chronic Hepatitis B Patients

  2007cited by this paper
• Changes in viral loads of lamivudine‐resistant mutants during entecavir therapy

  2007cited by this paper
• The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.

  2007cited by this paper
• [HBV gene variants and polymerse gene mutations in children with chronic hepatitis B in the course of the antiviral therapy].

  2007cited by this paper
• Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double‐blind trial

  2007cited by this paper
• Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.

  2007cited by this paper
• SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.

  2007cited by this paper
• Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug‐resistant variants during lamivudine therapy: Analyses of the polymerase gene and full‐length sequences

  2007cited by this paper
• A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.

  2006cited by this paper
• Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.

  2006cited by this paper
• Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam

  2006cited by this paper
• Hepatitis B genotype and YMDD profiles in an untreated Irish population.

  2006cited by this paper
• Absence of pretreatment markers that predict the emergence of YMDD mutants during lamivudine treatment--the results of a prospective multi-center study.

  2006cited by this paper
• Molecular Epidemiology of Hepatitis B Virus (HBV) Genotypes and Serotypes in Patients with Chronic HBV Infection in Korea

  2006cited by this paper
• YMDD mutations and genotypes of hepatitis B virus in northern China.

  2006cited by this paper
• Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance

  2005cited by this paper
• Response to long‐term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance

  2005cited by this paper
• HBV-DNA Suppression and Disease Course in HBV Cirrhosis Patients on Long-Term Lamivudine Therapy

  2005cited by this paper
• Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B

  2005influential reference
• YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.

  2005cited by this paper
• Significance of Viral Load, Core Promoter/Precore Mutations and Specific Sequences of Polymerase Gene in Hbv-Infected Patients on 3-Year Lamivudine Treatment

  2005cited by this paper
• Favorable efficacy of long‐term lamivudine therapy in patients with chronic hepatitis B: An 8‐year follow‐up study

  2005cited by this paper
• Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population.

  2005cited by this paper
• Overlapping Gene Mutations of Hepatitis B Virus in a Chronic Hepatitis B Patient with Hepatitis B Surface Antigen Loss during Lamivudine Therapy

  2005cited by this paper
• Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.

  2005influential reference
• Virological and Biochemical Relapse after Discontinuation of Lamivudine Monotherapy for Chronic Hepatitis B in Japan: Comparison with Breakthrough Hepatitis during Long-Term Treatment

  2005cited by this paper
• Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.

  2005cited by this paper
• Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experience

  2005cited by this paper
• The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B

  2005cited by this paper
• Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy

  2005cited by this paper
• Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance.

  2005cited by this paper
• Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine‐resistant mutants

  2005cited by this paper
• Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients

  2005cited by this paper
• Long-Term Follow-Up Study of Chinese Patients with YMDD Mutations: Significance of Hepatitis B Virus Genotypes and Characteristics of Biochemical Flares

  2004cited by this paper
• Hepatitis B virus genotyping based on cluster analysis of the region involved in lamivudine resistance.

  2004cited by this paper
• Chronic hepatitis B: Update of recommendations

  2004cited by this paper
• Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes

  2004cited by this paper
• Basal Core Promoter and Precore Mutations in the Hepatitis B Virus Genome Enhance Replication Efficacy of Lamivudine-Resistant Mutants

  2004cited by this paper
• Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long‐term lamivudine therapy for hepatitis B e antigen‐positive chronic hepatitis B

  2004cited by this paper
• Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments.

  2004cited by this paper
• Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter.

  2004cited by this paper
• Prospective Study on Lamivudine‐Resistant Hepatitis B in Renal Allograft Recipients

  2004cited by this paper
• Usefulness of dried blood samples for quantification and molecular characterization of HBV‐DNA

  2004cited by this paper
• Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

  2004cited by this paper
• Molecular epidemiology of hepatitis B and C virus infections in Asia

  2004cited by this paper
• Viral features of lamivudine resistant hepatitis B genotypes A and D

  2004cited by this paper
• Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations.

  2003cited by this paper
• Mannose-binding lectin gene polymorphisms and hepatitis B virus infection in Vietnamese patients.

  2003cited by this paper
• Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization.

  2003cited by this paper
• Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study.

  2003cited by this paper
• Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan

  2003cited by this paper
• Genotypic and Phenotypic Resistance: Longitudinal and Sequential Analysis of Hepatitis B Virus Polymerase Mutations in Patients With Lamivudine Resistance After Liver Transplantation

  2003cited by this paper
• Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy

  2003cited by this paper
• Hepatitis B Genotypes in Chronic Hepatitis B and Lamivudine Therapy

  2003cited by this paper
• Short-Term Lamivudine Therapy in Patients with Chronic Hepatitis B

  2003cited by this paper
• The relationship between HBV lamivudine resistance and HBV genotypes or basic core promoter mutations.

  2003cited by this paper
• The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

  2003cited by this paper
• Virological and biochemical relapse according to YMDD motif mutant type during long‐term lamivudine monotherapy

  2003cited by this paper
• YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine

  2003cited by this paper
• Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.

  2003cited by this paper
• The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

  2003cited by this paper
• Diagnosis and management of pre‐core mutant chronic hepatitis B

  2001cited by this paper
• Therapeutic advances in the management of hepatitis B and hepatitis C

  2001cited by this paper
• YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient.

  2001cited by this paper
• Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.

  2000cited by this paper
• Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation

  1999cited by this paper
• Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.

  1999cited by this paper
• Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN –

  year unknowncited by this paper

• Finite Treatments for Viral Hepatitis: Is "Sustained Control" Versus Cure Acceptable for HBV?

  2025cites this paper
• Detection and Genetic Characterization of Hepatitis B and D Viruses: A Multi-Site Cross-Sectional Study of People Who Use Illicit Drugs in the Amazon Region

  2021cites this paper
• Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects

  2021cites this paper
• [Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].

  2019cites this paper
• Current state-of-the-art pharmacotherapy for the management of hepatitis B infection

  2019cites this paper
• Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression

  2018cites this paper
• Assembly Properties of Hepatitis B Virus Core Protein Mutants Correlate with Their Resistance to Assembly-Directed Antivirals

  2018cites this paper
• THE EXISTENCE OF GENE DEOXYRIBONUCLEIC ACID POLYMERASE MUTATION FROM POSITIVE HEPATITIS B SAMPLES IN BANDUNG, INDONESIA

  2017cites this paper
• Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy.

  2016cites this paper
• Hepatitis B virus resistance substitutions: long-term analysis by next-generation sequencing

  2016cites this paper
• Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.

  2016cites this paper
• Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.

  2016cites this paper
• Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China

  2015cites this paper
• Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.

  2015cites this paper
• Epidemiology of Acute Hepatitis B in the United States From Population-Based Surveillance, 2006-2011.

  2015cites this paper
• Prevalence of YMDD Variants Leading to Lamivudine Resistance among Chronic HBV Patients in Gaza Strip-Palestine

  2015cites this paper
• Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta‐analysis

  2015cites this paper
• Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

  2015cites this paper
• Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients.

  2015cites this paper
• HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D

  2014cites this paper
• A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B

  2013cites this paper
• Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in central China

  2013cites this paper
• Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype

  2013cites this paper
• Demonstration of mutations conferring resistance to lamivudine in liver tissue of chronic hepatitis B patients under lamivudine therapy

  2013cites this paper
• Evaluation of a "home-made" method to determine viral genotype and characterize mutations conferring drug resistance in chronic hepatitis B patients.

  2012cites this paper
• Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue‐untreated and ‐treated patients with chronic hepatitis B in a hospital in China

  2012influential citation
• Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.

  2012cites this paper
• Antiviral therapies: focus on hepatitis B reverse transcriptase.

  2012cites this paper
• Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.

  2012cites this paper
• Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.

  2012cites this paper
• Lamivudine-Resistant HBV Infection in HIV-Positive Patients Receiving Antiretroviral Therapy in a Public Routine Clinic in Cameroon

  2012cites this paper
• Prevalence and endemicity

  2011cites this paper
• Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots.

  2011cites this paper
• HBV Genotypes: Relevance to Natural History, Pathogenesis and Treatment of Chronic Hepatitis B

  2011cites this paper
• Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.

  2011cites this paper
• Genotypic distribution of hepatitis B virus (HBV) among acute cases of HBV infection, selected United States counties, 1999-2005.

  2011cites this paper
• Hepatitis B genotypes: Role of testing in clinical practice

  2011cites this paper
• Emerging pipeline drugs for hepatitis B infection

  2011cites this paper
• Management of Chronic Hepatitis B: Status and Challenges beyond Treatment Guidelines

  2010cites this paper